Introduction {#sec1}
============

It is known that N-fused hybrid structures exhibit characteristic biological activities that are not shown in each homonuclear scaffolds. Pyrimidine- and quinazoline-fused benzimidazole hybrid scaffolds, benzo\[4,5\]imidazo\[1,2-*c*\]-pyrimidines ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **A**) and -quinazolines ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **B**), have been synthesized due to their intrinsic biological activities.^[@ref1]−[@ref3]^ We have also recently reported that 2-(2-bromovinyl)- and 2-(2-bromophenyl)-benzimidazoles are coupled and cyclized with cyanamide in the presence of a copper catalyst to give such N-fused hybrid scaffolds.^[@ref4]^ In connection with this report, it is known that primary amides can serve as building blocks for the construction of N-heterocycles by a copper-catalyzed coupling and cyclization reaction.^[@ref5],[@ref6]^ Ma and co-workers reported that N-substituted *o*-bromobenzamides react with primary amides in the presence of CuI to give quinazolinones.^[@ref7]^ While the present work was being performed, such a similar coupling and cyclization reaction leading to imidazo\[1,2-*c*\]quinazolines was also exemplified by the reaction of 2-(2-bromoaryl)-1*H*-imidazoles and formamide under CuI catalysis.^[@ref8]^ As part of our continuing studies directed toward transition-metal-catalyzed synthesis of N-fused hybrid scaffolds,^[@ref4],[@ref9]^ we provide here a new synthetic method for benzo\[4,5\]imidazo\[1,2-*c*\]-pyrimidines and -quinazolines by copper-catalyzed coupling and cyclization of 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles with primary amides as building blocks. In addition, this report also shows the synthesis of unprecedented N-fused hybrid scaffolds, benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-6,9-diones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **C**) and benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-diones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **D**), from methoxy-substituted **A** and **B** derivatives on benzimidzole moiety. To the best of our knowledge, no reports are found for the synthesis of **C** and **D** scaffolds. Only one example for the synthesis of N-fused hybrid analogue of **C**, benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-6,9-dione, is known.^[@ref10]^ However, several \[1,2-*a*\]alicyclic ring-fused benzimidazolequinones have been synthesized and tested for biological activity.^[@ref11]^ Benzimidazole-based 1,4-quinone (1*H*-benzo\[*d*\]imidazole-4,7-dione)-containing compounds has received pivotal attention in the development of bioreductive quinone-based drugs due to a wide spectrum of biological activities, such as anticancer, cytotoxic, antitumor, and antiproliferative activities.^[@ref11],[@ref12]^

![N-Fused Hybrid Scaffolds](ao-2018-00805z_0003){#sch1}

Results and Discussion {#sec2}
======================

Treatment of 2-(2-bromovinyl)benzimidazole **1a** with equimolar amount of formamide (**2a**) in dimethylformamide (DMF) at 110 °C for 24 h in the presence of CuI along with Cs~2~CO~3~ afforded 1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3a**) in 31% isolated yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). It is known that N-substituted *o*-bromobenzamides are effectively coupled and cyclized with primary amides in the presence of CuI along with additional amino acid to give quinazolinones.^[@ref7]^ Higher yield of **3a** was observed with further addition of [l]{.smallcaps}-proline (L~1~) as ligand ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). The yield of **3a** gradually increased with an increase of the molar ratio of **2a** to **1a** up to 2 ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--4). Other ligands, such as glycine (L~2~), 2-picolinic acid (L~3~), and 1,10-phenanthroline (L~4~), combined with CuI were not effective for the formation of **3a** like [l]{.smallcaps}-proline ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 4--7). The reaction proceeded with other bases, such as K~2~CO~3~, K~3~PO~4~, NaO^*t*^Bu, and Bu~3~N, using CuI and [l]{.smallcaps}-proline, but the yield of **3a** was generally lower than that by the use of Cs~2~CO~3~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--11). Among solvents examined under the employed conditions, DMF was shown to be the solvent of choice ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 4, 12, and 13). Other copper catalysts, such as CuBr, CuCl, or Cu powder, combined with [l]{.smallcaps}-proline showed lower catalytic activity than CuI ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 14--16). However, the reaction did not proceed at all toward **3a** in the absence of copper catalyst ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 17). We have recently reported the synthesis of heterocycles by copper-catalyzed coupling and cyclization under microwave irradiation to increase the reaction rate and to obtain an acceptable yield of product.^[@ref4],[@cit9a],[@ref13]^ When **1a** was treated with **2a** in DMF at 110 °C for 1 h in the presence of CuI/[l]{.smallcaps}-proline and Cs~2~CO~3~ under microwave irradiation (initial power, 100 W), **3a** was obtained in 71% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 18). Higher reaction temperature up to 130 °C resulted in a slightly increased yield of **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 19). As is the case for the usual heating conditions, lower yield of **3a** was observed in the absence of [l]{.smallcaps}-proline ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 20).

###### Optimization of Conditions for the Reaction of **1a** and **2a**[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-00805z_0008){#fx1}

  entry                                                                   \[**2a**\]/\[**1a**\]   Cu catalyst   ligand   base         solvent       yield[b](#t1fn2){ref-type="table-fn"} (%)
  ----------------------------------------------------------------------- ----------------------- ------------- -------- ------------ ------------- -------------------------------------------
  1                                                                       1                       CuI                    Cs~2~CO~3~   DMF           31
  2                                                                       1                       CuI           L~1~     Cs~2~CO~3~   DMF           51
  3                                                                       1.5                     CuI           L~1~     Cs~2~CO~3~   DMF           59
  4                                                                       2                       CuI           L~1~     Cs~2~CO~3~   DMF           70
  5                                                                       2                       CuI           L~2~     Cs~2~CO~3~   DMF           64
  6                                                                       2                       CuI           L~3~     Cs~2~CO~3~   DMF           49
  7                                                                       2                       CuI           L~4~     Cs~2~CO~3~   DMF           32
  8                                                                       2                       CuI           L~1~     K~2~CO~3~    DMF           41
  9                                                                       2                       CuI           L~1~     K~3~PO~4~    DMF           37
  10                                                                      2                       CuI           L~1~     NaO^*t*^Bu   DMF           51
  11                                                                      2                       CuI           L~1~     Bu~3~N       DMF           28
  12                                                                      2                       CuI           L~1~     Cs~2~CO~3~   DMSO          42
  13                                                                      2                       CuI           L~1~     Cs~2~CO~3~   1,4-dioxane   11
  14                                                                      2                       CuBr          L~1~     Cs~2~CO~3~   DMF           51
  15                                                                      2                       CuCl          L~1~     Cs~2~CO~3~   DMF           41
  16                                                                      2                       Cu powder     L~1~     Cs~2~CO~3~   DMF           43
  17                                                                      2                                     L~1~     Cs~2~CO~3~   DMF           0
  18[c](#t1fn3){ref-type="table-fn"}                                      2                       CuI           L~1~     Cs~2~CO~3~   DMF           71
  19[c](#t1fn3){ref-type="table-fn"}^,^[d](#t1fn4){ref-type="table-fn"}   2                       CuI           L~1~     Cs~2~CO~3~   DMF           78
  20[c](#t1fn3){ref-type="table-fn"}^,^[d](#t1fn4){ref-type="table-fn"}   2                       CuI                    Cs~2~CO~3~   DMF           64

Reaction conditions: **1a** (0.3 mmol), **2a** (0.6 mmol), Cu catalyst (0.03 mmol), ligand (0.09 mmol), base (0.9 mmol), solvent (3 mL), 110 °C, 24 h, unless otherwise stated.

Isolated yield.

Under microwave irradiation (100 W of initial power), 110 °C, 1 h, unless otherwise stated.

At 130 °C.

Having optimized the reaction conditions (condition A: entry 4 of [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}; condition B: entry 19 of [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), various 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles **1** were subjected to the reaction with primary amides **2** to investigate the reaction scope, and several representative results are summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. The coupling and cyclization of **1a** with primary amides **2b**--**d** also proceeded to give the corresponding benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines **3b**--**d** in good yields. Benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine **3e** was also formed from **1b** and **2a** in similar yields irrespective of methyl substituent on **1b**. The six-membered 2-(2-bromovinyl)benzimidazoles (**1c** and **1d**) also reacted with **2a** to give the corresponding benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines (**3f** and **3g**), irrespective of the presence of the methyl and phenyl substituents on **1c** and **1d**. With cyclic 2-(2-bromovinyl)benzimidazoles **1e**--**g** having various ring sizes, the corresponding benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines **3h**--**j** were also produced in 54--80% yields and the yield decreased with the increase in ring size. The coupling and cyclization of benzo-fused 2-(2-bromovinyl)benzimidazole **1h** took place with **1a** to give 5,6-dihydrobenzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3k**) in 57% yield. The reaction of acyclic 2-(2-bromovinyl)benzimidazoles (**1i** and **1j**) with **2a** also afforded the coupled and cyclized products **3l** and **3m** in 53 and 51% yields, respectively. Similar treatment of 2-(2-bromoaryl)benzimidazoles **1k**--**m** with primary amides **2a**--**c** under the employed conditions also afforded the corresponding quinazoline-fused benzimidazoles **3n**--**r** in 53--71% yields. As shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, higher product yields were observed under condition B compared to condition A.

###### Cu-Catalyzed Coupling and Cyclization of **1** with **2** Leading to **3**[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-00805z_0006){#fx2}

Reaction conditions: **1** (0.3 mmol), **2** (0.6 mmol) CuI (0.03 mmol), [l]{.smallcaps}-proline (0.09 mmol), Cs~2~CO~3~ (0.9 mmol), and DMF (3 mL). Condition A: 110 °C, 24 h. Condition B: 130 °C, 1 h, under microwave irradiation (100 W of initial power).

On the basis of the reaction of 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles with primary amides, the present protocol can be extended to the reaction with 4,7-dimethoxy-substituted benzimidazole analogues. [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} shows several results for further optimization with 2-(2-bromophenyl)-4,7-dimethoxy-1*H*-benzo\[*d*\]imidazole (**4a**) and **2a** to realize the effective formation of quinazoline-fused dimethoxybenzimidazole **5**. Similar treatment of **4a** with **2a** under condition B ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 19) afforded **5a** in only 43% yield along with concomitant formation of 4,7-dimethoxy-2-phenyl-1*H*-benzo\[*d*\]imidazole (**6**, 46% yield) by debromination of **4a** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 1). When **4a** was treated in the absence of **2a** under the employed conditions, **4a** was recovered almost completely (99%). This result indicates that formamide (**2a**) plays a significant role in debromination. In contrast to the results from the reaction of **1a** with **2a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 1 and 2, 19 and 20), performing the reaction in the absence of [l]{.smallcaps}-proline resulted in similar yield of **5a** without the formation of debromination byproduct ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 2). Higher loading of CuI was needed for an allowable yield of **5a** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 3). After further tuning reaction variants, such as Cu catalyst, base, and solvent ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 4--11), the best result in terms of the yield of product **5a** and complete conversion of **4a** was obtained with the standard set of reaction conditions shown in entry 7 of [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}.

###### Optimization of Conditions for the Reaction of **4a** and **2a**[a](#t3fn1){ref-type="table-fn"}

![](ao-2018-00805z_0001){#fx3}

  entry                                                                  Cu catalyst   base         solvent       yield[b](#t3fn2){ref-type="table-fn"} (%)
  ---------------------------------------------------------------------- ------------- ------------ ------------- -------------------------------------------
  1[c](#t3fn3){ref-type="table-fn"}^,^[d](#t3fn4){ref-type="table-fn"}   CuI           Cs~2~CO~3~   DMF           43
  2[d](#t3fn4){ref-type="table-fn"}                                      CuI           Cs~2~CO~3~   DMF           47
  3                                                                      CuI           Cs~2~CO~3~   DMF           63
  4                                                                      CuBr          Cs~2~CO~3~   DMF           59
  5                                                                      CuCl          Cs~2~CO~3~   DMF           51
  6                                                                      Cu powder     Cs~2~CO~3~   DMF           28
  7                                                                      CuI           K~2~CO~3~    DMF           81
  8                                                                      CuI           K~3~PO~4~    DMF           77
  9                                                                      CuI           NaO^*t*^Bu   DMF           69
  10                                                                     CuI           K~2~CO~3~    DMSO          51
  11                                                                     CuI           K~2~CO~3~    1,4-dioxane   42

Reaction conditions: **4a** (0.3 mmol), **2a** (0.6 mmol), Cu catalyst (0.06 mmol), base (0.9 mmol), solvent (3 mL), microwave irradiation (initial power, 100 W), 130 °C, 1 h, unless otherwise stated.

Isolated yield.

In the presence of [l]{.smallcaps}-proline (0.09 mmol).

CuI (0.03 mmol).

The coupling and cyclization could be applied to many 4,7-dimethoxybenzimidazoles **4** with primary amides under the conditions shown in entry 7 of [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} (condition C), and several representative results are summarized in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}. From the reaction of **4a** with an array of primary amides **2b**--**g**, the corresponding quinazoline-fused 4,7-dimethoxybenzimidazoles **5b**--**g** also invariably formed irrespective of the identity of primary amides. 2-(2-Bromovinyl)-4,7-dimethoxybenzimidazole **4b** was also readily coupled and cyclized with primary amides **2a**--**e** to give the corresponding pyrimidine-fused 4,7-dimethoxybenzimidazoles **5h**--**l** in the range of 71--81% yields. As is the case for the reaction of **1** with **2**, cyclic 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles **4c**--**f** having various ring sizes also reacted with **2a** to afford pyrimidine-fused 4,7-dimethoxybenzimidazoles **5m**--**p** in similar yields. Acyclic 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles (**4g** and **4h**) were also reacted with **2a** to give pyrimidine-fused 4,7-dimethoxybenzimidazoles (**5q** and **5r**).

###### Cu-Catalyzed Coupling and Cyclization of **4** with **2** Leading to **5**[a](#t4fn1){ref-type="table-fn"}

![](ao-2018-00805z_0005){#fx4}

Reaction conditions: **4** (0.3 mmol), **6** (0.6 mmol) CuI (0.06 mmol), K~2~CO~3~ (0.9 mmol), DMF (3 mL), 130 °C, 1 h, under microwave irradiation (100 W of initial power).

As shown in [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}, all quinazoline- and pyrimidine-fused dimethoxybenzimidazoles **5a**--**r** could be converted into unprecedented quinazoline- and pyrimidine-fused benzimidazolequinones **7a**--**r** with 70--89% yields by treatment of ceric ammonium nitrate (CAN) in aqueous acetonitrile.^[@cit12a],[@cit12f],[@ref14]−[@ref16]^

###### CAN-Mediated Oxidation of **5**--**7**[a](#t5fn1){ref-type="table-fn"}

![](ao-2018-00805z_0002){#fx5}

Reaction conditions: **5** (0.1 mmol), CAN (0.4 mmol), acetonitrile/H~2~O (4 mL), rt, 20 min.

The reaction pathway seems to proceed via an initial formation of C--N-coupled intermediate by copper-catalyzed Ullmann-type coupling between **1** (or **4**) and **2**, followed by cyclization and dehydration.^[@ref8],[@ref17]^ We confirmed that a similar treatment of *N*-methyl-2-(2-bromophenyl)benzimidazole **8** with benzamide (**2c**) under the employed conditions afforded C--N-coupled intermediate **9** in 70% yield ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![](ao-2018-00805z_0004){#sch2}

Conclusions {#sec3}
===========

In summary, we have developed a new synthetic method for benzo\[4,5\]imidazo\[1,2-*c*\]-pyrimidines and -quinazolines by copper-catalyzed coupling and cyclization of 2-(2-bromovinyl)- and 2-(2-bromoaryl)-benzimidazoles with primary amides. Such scaffolds having methoxy group on benzimidzole moiety could be transformed into unprecedented N-fused hybrid scaffolds, benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-6,9-diones and benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-diones, by treatment with aqueous ceric ammonium nitrate. Further challenges on the synthesis of novel benzimidazole-based 1,4-quinone-containing N-fused hybrid heterocyclic compounds using the present protocol are expected.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

^1^H (400 and 500 MHz) and ^13^C NMR (100 and 125 MHz) spectra were recorded in CDCl~3~ or DMSO-*d*~6~. Melting points were determined on a microscopic melting point apparatus. High-resolution mass data were recorded by electronic ionization (HRMS-EI, magnetic sector--electric sector double-focusing mass analyzer) at Korea Basic Science Center, Daegu, Korea. All microwave reactions (CEM, Discover LabMate) were carried out in sealed tube (5 mL), and maintenance of the reaction temperature was monitored by an external infrared sensor. Isolation of pure products was carried out by thin-layer (a glass plate coated with Kieselgel 60 GF~254~, Merck) chromatography. 2-(2-Bromovinyl)benzimidazoles and 2-(2-bromoaryl)benzimidazoles were prepared from the corresponding carboxylic acids (or aldehydes) and 1,2-phenylenediamines by literature procedures.^[@cit3g],[@cit11a],[@ref18]^ Commercially available organic and inorganic compounds were used without further purification.

General Procedure for the Synthesis of **3** (Condition A) {#sec4.2}
----------------------------------------------------------

To a 5 mL screw-capped vial was added **1** (0.3 mmol) and **2** (0.6 mmol), together with CuI (0.006 g, 0.03 mmol), [l]{.smallcaps}-proline (0.010 g, 0.09 mmol), Cs~2~CO~3~ (0.293 g, 0.9 mmol), and DMF (3 mL). The reaction mixture was stirred at 110 °C for 24 h. The mixture was then cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to remove inorganic components. Removal of the solvent left a crude mixture, which was separated by thin-layer chromatography (TLC) (dichloromethane/MeOH = 99:1) to give **3**.

General Procedure for the Synthesis of **3** (Condition B) {#sec4.3}
----------------------------------------------------------

A 5 mL microwave reaction tube was charged with **1** (0.3 mmol) and **2** (0.6 mmol), together with CuI (0.006 g, 0.03 mmol), [l]{.smallcaps}-proline (0.010 g, 0.09 mmol), Cs~2~CO~3~ (0.293 g, 0.9 mmol), and DMF (3 mL). The reaction mixture was heated to 130 °C for 1 h by microwave irradiation at 100 W initial power. The mixture was then cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to remove inorganic components. Removal of the solvent left a crude mixture, which was separated by TLC (dichloromethane/MeOH = 99:1) to give **3**. Except for known **3n**,^[@ref19]^**3o**,^[@ref19]^ and **3p**,^[@cit3g]^ all new products were characterized spectroscopically.

### 1,2,3,4-Tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3a**) {#sec4.3.1}

Pale yellow solid (52 mg, 78%). Mp 204--206 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.89--1.99 (m, 4H), 2.88--2.91 (m, 2H), 3.06--3.09 (m, 2H), 7.36--7.40 (m, 1H), 7.52--7.56 (m, 1H), 7.91--7.94 (m, 2H), 9.10 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 21.7, 22.7, 23.5, 31.5, 110.6, 119.8, 120.2, 122.2, 126.8, 127.2, 135.9, 144.8, 148.4, 150.7. HRMS (EI) anal. calcd for C~14~H~13~N~3~ (M^+^): 223.1109. Found: 223.1108.

### 6-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3b**) {#sec4.3.2}

Pale yellow solid (47 mg, 66%). Mp 174--176 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.84--1.87 (m, 4H), 2.76--2.77 (m, 2H), 2.98--2.99 (m, 2H), 3.02 (s, 3H), 7.26--7.30 (m, 1H), 7.44--7.48 (m, 1H), 7.86--7.92 (m, 2H). ^13^C NMR (100 MHz, CDCl~3~): δ 21.9, 22.8, 23.3, 23.7, 31.3, 114.5, 117.2, 120.0, 121. 9, 126.2, 128.7, 145.3, 147.6, 149.8, 150.1. HRMS (EI) anal. calcd for C~15~H~15~N~3~ (M^+^): 237.1266. Found: 237.1265.

### 6-Phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3c**) {#sec4.3.3}

Pale yellow solid (64 mg, 71%). Mp 186--188 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.94--2.02 (m, 4H), 2.92--2.95 (m, 2H), 3.13--3.16 (m, 2H), 6.67 (d, *J* = 8.3 Hz, 1H), 7.01--7.04 (m, 1H), 7.41--7.45 (m, 1H), 7.59--7.68 (m, 5H), 7.90 (d, *J* = 8.4 Hz, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 21.9, 22.8, 23.5, 31.5, 114.7, 118.2, 119.8, 121.5, 126.2, 128.3, 128. 5, 129.4, 131.0, 134.3, 145.1, 148.8, 150.0, 150.4. HRMS (EI) anal. calcd for C~20~H~17~N~3~ (M^+^): 299.1422. Found: 299.1420.

### 6-Benzyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3d**) {#sec4.3.4}

Pale yellow solid (55 mg, 59%). Mp 190--192 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.86--1.94 (m, 4H), 2.81--2.84 (m, 2H), 3.02--3.05 (m, 2H), 4.71 (s, 2H), 7.10--7.16 (m, 6H), 7.38--7.42 (m, 1H), 7.72 (d, *J* = 8.6 Hz, 1H), 7.84 (d, *J* = 8.4 Hz, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 22.0, 22.8, 23.5, 31.4, 41.8, 115.0, 117.8, 119.9, 122.0, 126.2, 127.4, 127.9, 128.3, 129.9, 134.7, 145.3, 148.5, 150.1, 150.2. HRMS (EI) anal. calcd for C~21~H~19~N~3~ (M^+^): 313.1579. Found: 313.1579.

### 9,10-Dimethyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3e**) {#sec4.3.5}

Pale yellow solid (57 mg, 76%). Mp 203--204 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.93--1.94 (m, 4H), 2.43 (s, 3H), 2.44 (s, 3H), 2.86--2.88 (m, 2H) 3.06 (s, 2H), 7.66 (d, *J* = 8.6 Hz, 2H), 9.01 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 20.7, 20.9, 21.8, 22.7, 23.4, 31.4, 110.6, 119.6, 120.0, 125.5, 131.7, 135.8, 136.1, 143.4, 147.9, 149.9. HRMS (EI) anal. calcd for C~16~H~17~N~3~ (M^+^): 251.1422. Found: 251.1421.

### 2-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3f**) {#sec4.3.6}

Pale yellow solid (43 mg, 61%). Mp 223--226 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.11 (d, *J* = 6.6 Hz, 3H), 1.49--1.57 (m, 1H), 1.89--1.9 (m, 2H), 2.49--2.56 (m, 1H), 2.85--2.89 (m, 2H) 3.20--3.25 (m, 1H), 7.31--7.35 (m, 1H), 7.46--7.50 (m, 2H), 9.05 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 21.6, 28.1, 30.9, 31.4, 31.7, 110.7, 119.4, 120.3, 122.3, 126.8, 127.3, 136.0, 144.9, 148.4, 150.5. HRMS (EI) anal. calcd for C~15~H~15~N~3~ (M^+^): 237.1266. Found: 237.1265.

### 2-Phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3g**) {#sec4.3.7}

Pale yellow solid (63 mg, 70%). Mp 201--203 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 2.09--2.19 (m, 1H), 2.33--2.36 (m, 1H), 3.05--3.21 (m, 4H), 3.51--3.61 (m, 1H), 7.25--7.2 (m, 1H), 7.35--7.37 (m, 4H), 7.42--7.46 (m, 1H), 7.56--7.60 (m, 1H), 7.94--7.99 (m, 1H), 9.18 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 29.9, 30.9, 31.8, 39.1, 110.8, 119.4, 120.3, 122.4, 126.7, 126.9, 127.0, 127.3, 128.7, 136.3, 144.9, 145.1, 148.2, 150.2. HRMS (EI) anal. calcd for C~20~H~17~N~3~ (M^+^): 299.1422. Found: 299.1422.

### 2,3,4,5-Tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*c*\]cyclohepta\[*e*\]pyrimidine (**3h**) {#sec4.3.8}

Pale yellow solid (57 mg, 80%). Mp 212--214 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.72--1.83 (m, 4H), 1.93--1.98 (m, 2H), 3.08--3.10 (m, 2H), 3.27--3.30 (m, 2H), 7.36--7.40 (m, 1H), 7.53--7.57 (m, 1H), 7.92--7.95 (m, 2H), 9.10 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 26.1, 26.6, 26.7, 32.6, 38.1, 110.9, 120.1, 122.0, 125.2, 127.0, 127.5, 135.6, 145.1, 149.2, 156.4. HRMS (EI) anal. calcd for C~15~H~15~N~3~ (M^+^): 237.1266. Found: 237.1264.

### 1,2,3,4,5,6-Hexahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cycloocta\[*e*\]pyrimidine (**3i**) {#sec4.3.9}

Pale yellow solid (52 mg, 69%). Mp 205--208 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.33--1.44 (m, 4H), 1.76--1.85 (m, 4H), 2.91--2.94 (m, 2H), 3.13--3.16 (m, 2H), 7.30--7.34 (m, 1H), 7.46--7.50 (m, 1H), 7.87 (d, *J* = 9.08 Hz, 2H), 9.08 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 25.8, 26.2, 26.6, 29.9, 30.2, 33.5, 110.8, 120.1, 122.1, 122.9, 126.9, 127.4, 136.5, 145.1, 148.51, 153.7. HRMS (EI) anal. calcd for C~16~H~17~N~3~ (M^+^): 251.1422. Found: 251.1422.

### 1,2,3,4,5,6,7,8,9,10-Decahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cyclododeca\[*e*\]pyrimidine (**3j**) {#sec4.3.10}

Pale yellow solid (50 mg, 54%). Mp 202--204 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 1.29--1.42 (m, 8H), 1.47--1.53 (m, 2H), 1.83--1.90 (m, 2H), 1.92--1.99 (m, 2H), 2.76--2.80 (m, 2H), 3.01--3.05 (m, 2H), 7.30--7.34 (m, 1H), 7.46--7.50 (m, 1H), 7.85--7.90 (m, 2H), 9.08 (s, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 22.6, 23.1, 24.5, 25.5, 25.8, 26.0, 26.8, 27.0, 30.8, 110.7, 120.2, 122.1, 122.9, 126.7, 127.1, 136.2, 145.0, 149.1, 153.4. HRMS (EI) anal. calcd for C~20~H~25~N~3~ (M^+^): 307.2048. Found: 307.2051.

### 5,6-Dihydrobenzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3k**) {#sec4.3.11}

Pale yellow solid (46 mg, 57%). Mp 191--193 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 3.07--3.11 (m, 2H), 3.15--3.20 (m, 2H), 7.28--7.44 (m, 2H), 7.45--7.49 (m, 2H), 7.60--7.64 (m, 2H), 9.22 (s, 1H), 9.29 (d, *J* = 7.6 Hz, 1H). ^13^C NMR (100 MHz, CDCl~3~): δ 28.3, 30.8, 110.7, 117.6, 120.6, 122.5, 126.7, 127.1, 127.3, 127.8, 128.7, 128.8, 130.3, 136.5, 136.9, 145.3, 146.0, 151.8. HRMS (EI) anal. calcd for C~18~H~18~N~3~ (M^+^): 271.1109. Found: 271.1111.

### 4-Methyl-3-phenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine (**3l**) {#sec4.3.12}

Pale yellow solid (41 mg, 53%). Mp 234--236 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 2.18 (s, 3H), 6.52 (d, *J* = 8.5 Hz, 1H), 7.24--7.27 (m, 1H), 7.70--7.73 (m, 1H), 7.74--7.76 (m, 2H), 7.98--8.03 (m, 3H), 8.25 (d, *J* = 8.3 Hz, 1H), 9.03 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 14.5, 110.5, 110.8, 119.4, 120.3, 124.7, 126.6, 127.5, 129.2, 129.9, 130.6, 140.9, 142.2, 147.2, 154.2. HRMS (EI) anal. calcd for C~17~H~13~N~3~ (M^+^): 259.1109. Found: 259.1111.

### 3,4-Diphenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine (**3m**) {#sec4.3.13}

Pale yellow solid (49 mg, 51%). Mp 262--264 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.12--7.14 (m, 4H), 7.17--7.19 (m, 3H), 7.20--7.24 (m, 2H), 7.30--7.32 (m, 3H), 7.52--7.55 (m, 1H), 8.30--8.32 (m, 1H), 9.33 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 110.6, 120.7, 121.4, 122.0, 126.4, 126.9, 127.9, 128.1, 128.8, 129.7, 130.2, 132.7, 136.1, 137.8, 145.3, 150.2, 163.4. HRMS (EI) anal. calcd for C~22~H~15~N~3~ (M^+^): 321.1266. Found: 321.1267.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3n**)^[@ref19]^ {#sec4.3.14}

Pale yellow solid (47 mg, 71%). Mp 245--247 °C (lit.^[@ref2]^ 247--249 °C). ^1^H NMR (500 MHz, CDCl~3~): δ 7.40--7.43 (m, 1H), 7.47--7.51 (m, 1H), 7.56--7.60 (m, 2H), 7.68--7.72 (m, 1H), 7.96 (d, *J* = 8.0 Hz, 1H), 8.75 (dd, *J* = 7.8 and 0.8 Hz, 1H), 8.78 (d, *J* = 8.3 Hz, 1H), 9.17 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 110.2, 114.4, 119.1, 122.4, 123.2, 123.8, 124.4, 125.1, 128.2, 131.8, 143.9, 144.7, 146.5, 148.5.

### 6-Methylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3o**)^[@ref19]^ {#sec4.3.15}

Pale yellow solid (43 mg, 61%). Mp 176--177 °C (lit.^[@ref2]^ 177--179 °C). ^1^H NMR (500 MHz, CDCl~3~): δ 3.13 (s, 3H), 7.36--7.39 (m, 1H), 7.52--7.57 (m, 1H), 7.61--7.65 (m, 1H), 7.73--7.77 (m, 1H), 7.83 (d, *J* = 8.0 Hz, 1H), 7.93--7.97 (m, 2H), 8.64--8.65 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 24.2, 114.4, 118.1, 120.2, 123.8, 124.4, 125.1, 127.3, 127.6, 129.2, 131.8, 142.2, 144.7, 147.5, 148.5.

### 6-Phenylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3p**)^[@cit3g]^ {#sec4.3.16}

Pale yellow solid (61 mg, 69%). Mp 227--228 °C (lit.^[@ref3]^ 230--231). ^1^H NMR (500 MHz, CDCl~3~): δ 6.60 (d, *J* = 8.3 Hz, 1H), 7.17--7.20 (m, 2H), 7.45--7.48 (m, 1H), 7.59--7.63 (m, 2H), 7.68--7.71 (m, 3H), 7.77--7.81 (m, 2H), 7.95--8.00 (m, 2H), 8.73 (dd, *J* = 7.8 and 0.8 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 114.5, 118.2, 120.2, 122.5, 123.3, 124.5, 125.2, 128.2, 128.4, 128.6, 129.3, 131.1, 132.0, 134.2, 142.1, 144.0, 148.1, 148.6.

### 2-Fluorobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3q**) {#sec4.3.17}

Pale yellow solid (38 mg, 53%). Mp 268--271 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.51--7.54 (m, 2H), 7.59--7.63 (m, 1H), 7.99--8.04 (m, 3H), 8.32 (dd, *J* = 8.4 and 2.9 Hz, 1H), 9.13 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 109.6 (d, *J* = 24.4 Hz), 110.2, 113.7 (d, *J* = 23.6 Hz), 120.3, 120.5, 123.4, 123.7, 126.4, 130.8 (d, *J* = 8.1 Hz), 131.0 (d, *J* = 9.1 Hz), 135.5 (d, *J* = 2.6 Hz), 139.2, 144.0, 161.9 (d, *J* =247.7 Hz). HRMS (EI) anal. calcd for C~14~H~8~FN~3~ (M^+^): 237.0702. Found: 237.0704.

### 2,3-Dimethoxybenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**3r**) {#sec4.3.18}

White solid (54 mg, 64%). Mp 227--229 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.92 (s, 3H), 3.94 (s, 3H), 7.13 (s, 1H), 7.32--7.35 (m, 1H), 7.59 (s, 1H), 7.66--7.70 (m, 1H), 7.75 (dd, *J* = 7.8 and 1.5 Hz, 1H), 9.18 (d, *J* = 8.7 Hz, 1H), 9.35 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 56.5, 57.1, 107.5, 107.8, 121.3, 122.5, 123.3, 127.0, 131.4, 136.1, 138.8, 140.3, 143.3, 149.1, 152.3, 160.6. HRMS (EI) anal. calcd for C~16~H~13~N~3~O~2~ (M^+^): 279.1008. Found: 279.1009.

General Procedure for the Synthesis of **5** (Condition C) {#sec4.4}
----------------------------------------------------------

A 5 mL microwave reaction tube was charged with **4** (0.3 mmol) and **2** (0.6 mmol), together with CuI (0.011 g, 0.06 mmol), K~2~CO~3~ (0.124 g, 0.9 mmol), and DMF (3 mL). The reaction mixture was heated to 130 °C for 1 h by microwave irradiation at 100 W initial power. The mixture was then cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to remove inorganic components. Removal of the solvent left a crude mixture, which was separated by TLC (hexane/EA = 2:1) to give **5**.

### 8,11-Dimethoxybenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5a**) {#sec4.4.1}

Pale yellow solid (23 mg, 81%). Mp 190--193 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.02 (s, 6H), 7.00 (s, 2H), 7.36--7.40 (m, 1H), 7.52--7.56 (m, 1H), 7.91--7.94 (m, 2H), 9.10 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 55.2, 110.2, 119.5, 120.2, 124.1, 126.6, 128.4, 128.5, 131.4, 132.9, 135.5, 135.2, 142.4, 145.7. HRMS (EI) anal. calcd for C~16~H~13~N~3~O~2~ (M^+^): 279.1008. Found: 279.1009.

### 8,11-Dimethoxy-6-methylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5b**) {#sec4.4.2}

Pale yellow solid (63 mg, 72%). Mp 188--190 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.25 (s, 3H), 4.00 (s, 6H), 6.64 (s, 2H), 6.93--6.96 (m, 1H), 7.13 (dd, *J* = 8.3 Hz, 1H), 7.33--7.37 (m, 1H), 7.60 (dd, *J* = 7.8 and 1.5 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 29.7, 56.5, 104.1, 112.0, 116.0, 118.1, 119.0, 124.5, 129.0, 131.8, 137.1, 138.7, 139.4, 150.1, 158.7. HRMS (EI) anal. calcd for C~17~H~15~N~3~O~2~ (M^+^): 293.1164. Found: 293.1166.

### 8,11-Dimethoxy-6-phenylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5c**) {#sec4.4.3}

Pale yellow solid (88 mg, 83%). Mp 214--217 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.97 (s, 3H), 4.09 (s, 3H), 6.64--6.68 (m, 2H), 7.18--7.21 (m, 1H), 7.48--7.52 (m, 1H), 7.54--7.58 (m, 3H), 7.74 (dd, *J* = 7.9 and 1.4 Hz, 1H), 8.49--8.51 (m, 2H), 9.10 (dd, *J* = 8.5 and 1.0 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 55.8, 56.1, 102.6, 104.2, 115.6, 119.8, 123.0, 124.9, 127.7, 127.8, 128.8, 130.6, 132.1, 133.3, 134.3, 138.3, 140.4, 145.0, 149.7, 164.7. HRMS (EI) anal. calcd for C~22~H~17~N~3~O~2~ (M^+^): 355.1321. Found: 355.1318.

### 6-Benzyl-8,11-dimethoxybenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5d**) {#sec4.4.4}

Pale yellow solid (95 mg, 86%). Mp 210--212 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.86 (s, 2H), 3.95 (s, 3H), 4.08 (s, 3H), 6.66 (s, 2H), 7.04--7.07 (m, 1H), 7.18--7.21 (m, 1H), 7.25--7.28 (m, 2H), 7.34--7.37 (m, 1H), 7.60--7.63 (m, 3H), 8.73 (dd, *J* = 8.4 and 0.9 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 46.4, 55.8, 56.1, 102.6, 104.2, 115.5, 116.8, 121.2, 122.8, 125.8, 126.9, 128.6, 129.4, 129.5, 130.9, 135.4, 136.9, 138.6, 149.0, 164.4, 170.4. HRMS (EI) anal. calcd for C~23~H~19~N~3~O~2~ (M^+^): 369.1477. Found: 369.1474.

### 8,11-Dimethoxy-6-propylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5e**) {#sec4.4.5}

Pale yellow solid (76 mg, 79%). Mp 206--209 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 0.97 (t, *J* = 7.4 Hz, 3H), 1.83--1.90 (m, 2H), 2.46--2.49 (m, 2H), 3.88 (s, 6H), 6.53 (s, 2H), 6.94--6.97 (m, 1H), 7.20--7.23 (m, 1H), 7.71 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.65 (dd, *J* = 8.4, 0.7 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 14.0, 19.1, 40.9, 55.9, 56.2, 103.2, 103.6, 115.7, 121.4, 122.8, 126.2, 127.1, 128.9, 130.4, 130.7, 138.5, 149.2, 149.9, 173.0. HRMS (EI) anal. calcd for C~19~H~19~N~3~O~2~ (M^+^): 321.1477. Found: 321.1476.

### 8,11-Dimethoxy-6-(pyridin-3-yl)benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5f**) {#sec4.4.6}

Pale yellow solid (79 mg, 74%). Mp 251--254 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.68 (s, 3H), 4.00 (s, 3H), 6.42--6.44 (m, 1H), 6.60 (s, 2H), 7.00--7.07 (m, 2H), 7.24--7.28 (m, 2H), 7.29--7.32 (m, 1H), 7.44--7.47 (m, 1H), 7.64--7.66 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 55.9, 56.0, 102.2, 104.3, 121.4, 124.1, 125.7, 126.6, 127.0, 127.2, 127.5, 125.5, 131.3, 131.6, 132.4, 132.5, 132.7, 137.4, 141.6, 146.2, 151.8. HRMS (EI) anal. calcd for C~21~H~16~N~4~O~2~ (M^+^): 356.1273. Found: 356.1275.

### 8,11-Dimethoxy-6-(thiophen-2-yl)benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5g**) {#sec4.4.7}

Pale yellow solid (78 mg, 72%). Mp 233--236 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.64 (s, 3H), 3.90 (s, 3H), 6.39 (dd, *J* = 7.7 and 1.6 Hz, 1H) 6.67 (d, *J* = 8.7 Hz, 1H), 6.72 (d, *J* = 8.7 Hz, 1H), 7.11--7.14 (m, 1H), 7.16--7.20 (m, 1H), 7.42--7.45 (m, 1H), 7.53 (dd, *J* = 7.9 and 1.3 Hz, 1H), 7.77--7.79 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 55.8, 56.2, 103.2, 104.9, 120.7, 123.3, 126.8, 127.8, 128.0, 129.1, 131.1, 132.0, 132.4, 132.8, 134.3, 136.5, 141.0, 145.7, 150.9, 162.3. HRMS (EI) anal. calcd for C~20~H~15~N~3~O~2~S (M^+^): 361.0885. Found: 361.0887

### 8,11-Dimethoxy-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5h**) {#sec4.4.8}

Pale yellow solid (65 mg, 76%). Mp 191--193 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.88--1.98 (m, 4H), 2.88--2.91 (m, 2H), 3.12--3.14 (m, 2H), 4.03 (s, 3H), 4.05 (s, 3H), 6.70 (d, *J* = 8.6 Hz, 1H), 6.81 (d, *J* = 8.6 Hz, 1H), 9.55 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.6, 22.6, 23.3, 31.3, 56.0, 102.1, 105.2, 118.0, 119.6, 136.6, 138.5, 143.0, 145.4, 147.5, 149.6. HRMS (EI) anal. calcd for C~16~H~17~N~3~O~2~ (M^+^): 283.1321. Found: 283.1318.

### 8,11-Dimethoxy-6-methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5i**) {#sec4.4.9}

Pale yellow solid (63 mg, 71%). Mp 179--181 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.14 (s, 3H), 1.89--1.98 (m, 4H), 2.88--2.91 (m, 2H), 3.12--3.14 (m, 2H), 4.03 (s. 3H), 4.05 (s, 3H), 6.70 (d, *J* = 8.6 Hz, 1H), 6.81 (d, *J* = 8.6 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 18.8, 21.6, 22.6, 23.3, 31.3, 56.0, 56.2, 102.1, 105.2, 118.0, 119.6, 136.6, 138.5, 143.0, 145.4, 147.4, 149.6. HRMS (EI) anal. calcd for C~17~H~19~N~3~O~2~ (M^+^): 297.1477. Found: 297.1475.

### 8,11-Dimethoxy-6-phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5j**) {#sec4.4.10}

Pale yellow solid (82 mg, 76%). Mp 186--188 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.97--2.07 (m, 4H), 2.97--2.99 (m, 2H), 3.20--3.23 (m, 2H), 3.96 (s, 3H), 4.00 (s, 3H), 6.61 (d, *J* = 8.6 Hz, 1H), 6.79 (d, *J* = 8.6 Hz, 1H), 7.00--7.07 (m, 2H), 7.24--7.28 (m, 2H), 7.29--7.32 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.6, 22.6, 23.3, 31.3, 55.8, 56.1, 102.6, 104.2, 119.9, 127.7, 127.9, 128.8, 130.6, 132.2, 133.3, 134.3, 138.4, 140.4, 145.1, 149.7. HRMS (EI) anal. calcd for C~22~H~21~N~3~O~2~ (M^+^): 359.1634. Found: 359.1633.

### 6-Benzyl-8,11-dimethoxy-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5k**) {#sec4.4.11}

Pale yellow solid (91 mg, 81%). Mp 193--196 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.95--2.05 (m, 4H), 2.95--2.97 (m, 2H), 3.18--3.21 (m, 2H), 3.92 (s, 2H), 4.10 (s, 3H), 4.11 (s, 3H), 6.76 (d, *J* = 8.6 Hz, 1H), 6.88 (d, *J* = 8.6 Hz, 1H), 7.24--7.27 (m, 1H), 7.31--7.34 (m, 2H), 7.66--7.69 (m, 2H). ^13^C NMR (125 MHz, CDCl~3~): δ 22.6, 23.6, 24.3, 32.3, 45.9, 55.6, 56.2, 103.1, 106.2, 115.0, 120.7, 122.3, 125.3, 126.4, 128.1, 129.0, 130.4, 135.0, 138.1. 148.5, 169.9. HRMS (EI) anal. calcd for C~22~H~21~N~3~O~2~ (M^+^): 373.1790. Found: 373.1792.

### 8,11-Dimethoxy-6-propyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5l**) {#sec4.4.12}

Pale yellow solid (76 mg, 78%). Mp 197--199 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 0.91 (t, *J* = 7.4, 3H), 1.62--1.70 (m, 2H), 1.81--1.89 (m, 4H), 2.41--2.44 (m, 2H), 2.79--2.82 (m, 2H), 3.03--3.05 (m, 2H), 3.94 (s, 3H), 3.95 (s, 3H), 6.61 (d, *J* = 8.6 Hz, 1H), 6.72 (d, *J* = 8.6 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 14.0, 19.1, 21.6, 22.6, 23.3, 31.3, 40.9, 55.9, 56.2, 103.2, 103.6, 121.4, 122.8, 126.2, 127.1, 128.9, 130.7, 138.5, 149.2. HRMS (EI) anal. calcd for C~19~H~23~N~3~O~2~ (M^+^): 325.1790. Found: 325.1791.

### 8,11-Dimethoxy-2-methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline (**5m**) {#sec4.4.13}

Pale yellow solid (62 mg, 70%). Mp 173--176 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.10 (d, *J* = 5.9 Hz, 3H), 1.45--1.52 (m, 1H), 1.88--1.96 (m, 2H), 2.41--2.45 (m, 1H), 2.80--2.85 (m, 2H), 3.15--3.22 (m, 1H), 3.92 (s, 3H), 4.00 (s, 3H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.93 (d, *J* = 8.5 Hz, 1H), 9.48 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.1, 27.0, 29.9, 30.4, 30.8, 55.8, 56.0, 102.7, 106.6, 117.8, 120.0, 135.5, 138.2, 142.5, 144.5, 145.7, 148.9. HRMS (EI) anal. calcd for C~17~H~19~N~3~O~2~ (M^+^): 297.1477. Found: 297.1474.

### 9,12-Dimethoxy-2,3,4,5-tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*c*\]cyclohepta\[*e*\]pyrimidine (**5n**) {#sec4.4.14}

Pale yellow solid (73 mg, 82%). Mp 194--196 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.74--1.78 (m, 2H), 1.90--1.99 (m, 4H), 2.87--2.89 (m, 2H), 3.57--3.59 (m, 2H), 3.96 (s, 3H), 4.05 (s, 3H), 6.65 (d, *J* = 8.6 Hz, 1H), 6.85 (d, *J* = 8.6 Hz, 1H), 9.17 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 25.1, 27.4, 30.7, 32.0, 34.0, 56.3, 56.5, 102.0, 105.8, 118.8, 122.7, 132.5, 136.3, 139.8, 145.5, 148.1, 150.2. HRMS (EI) anal. calcd for C~17~H~19~N~3~O~2~ (M^+^): 297.1477. Found: 297.1479.

### 10,13-Dimethoxy-1,2,3,4,5,6-hexahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cycloocta\[*e*\]pyrimidine (**5o**) {#sec4.4.15}

Pale yellow solid (74 mg, 79%). Mp 210--212 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.33--1.37 (m, 2H), 1.44--1.48 (m, 2H), 1.72--1.77 (m, 2H), 1.88--1.92 (m, 2H), 2.79--2.82 (m, 2H), 3.65--3.67 (m, 2H), 3.93 (s, 3H), 4.03 (s, 3H), 6.66 (d, *J* = 8.7 Hz, 1H), 6.82 (d, *J* = 8.7 Hz, 1H), 9.14 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 25.8, 26.1, 29.1, 29.5, 29.7, 31.8, 56.0, 56.3, 102.2, 105.4, 118.8, 119.8, 132.0, 135.5, 139.8, 144.8, 145.4, 150.5. HRMS (EI) anal. calcd for C~18~H~21~N~3~O~2~ (M^+^): 311.1634. Found: 311.1631.

### 14,17-Dimethoxy-1,2,3,4,5,6,7,8,9,10-decahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cyclododeca\[*e*\]pyrimidine (**5p**) {#sec4.4.16}

Pale yellow solid (72 mg, 65%). Mp 199--202 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.35--1.47 (m, 8H), 1.51--1.59 (m, 4H), 1.61--1.69 (m, 2H), 1.78--1.83 (m, 2H), 2.79--2.82 (m, 2H), 3.65--3.68 (m, 2H), 3.98 (s, 3H), 4.06 (s, 3H), 6.72 (d, *J* = 8.7 Hz, 1H), 6.87 (d, *J* = 8.7 Hz, 1H), 9.27 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.9, 22.8, 24.6, 24.7, 25.5, 25.9, 26.5, 27.0, 28.2, 29.7, 56.0, 56.4, 102.3, 105.4, 119.3, 119.5, 130.1, 134.0, 138.0, 143.1, 143.3, 149.6. HRMS (EI) anal. calcd for C~22~H~29~N~3~O~2~ (M^+^): 367.2260. Found: 367.2261.

### 6,9-Dimethoxy-4-methyl-3-phenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine (**5q**) {#sec4.4.17}

Pale yellow solid (65 mg, 68%). Mp 219--221 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 2.14 (s, 3H), 3.94 (s, 3H), 4.05 (s, 3H), 6.37 (d, *J* = 8.6 Hz, 1H), 6.78 (d, *J* = 8.6 Hz, 1H), 7.31--7.34 (m, 2H), 7.51--7.53 (m, 3H), 9.37 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 15.9, 55.7, 56.4, 101.7, 105.7, 115.5, 118.6, 128.2, 128.3, 129.2, 130.6, 132.8, 137.1, 140.4, 142.2, 146.0, 152.4. HRMS (EI) anal. calcd for C~19~H~17~N~3~O~2~ (M^+^): 319.1321. Found: 319.1319.

### 6,9-Dimethoxy-3,4-diphenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine (**5r**) {#sec4.4.18}

Pale yellow solid (80 mg, 70%). Mp 211--212 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.02 (s, 3H), 4.09 (s, 3H), 6.68 (d, *J* = 8.6 Hz, 1H), 6.85 (d, *J* = 8.6 Hz, 1H), 7.25--7.28 (m, 4H), 7.31--7.37 (m, 4H), 7.51--7.53 (m, 2H), 9.79 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 56.3, 57.4, 102.0, 107.2, 118.1, 121.7, 128.2. 129.1, 129.9, 130.3, 130.6, 136.4, 136.9, 137.8, 138.4, 143.9, 146.1, 149.6, 162.7. HRMS (EI) anal. calcd for C~24~H~19~N~3~O~2~ (M^+^): 381.1477. Found: 381.1474.

### 4,7-Dimethoxy-2-phenyl-1*H*-benzo\[*d*\]imidazole (**6**) {#sec4.4.19}

White solid (37 mg, 48%). Mp 223--225 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.88 (s, 6H), 6.63 (s, 2H), 7.72--7.76 (m, 3H), 8.07--8.11 (m, 2H). ^13^C NMR (125 MHz, DMSO): δ 55.9, 103.0, 125.4, 129.1, 130.1, 130.4, 131.0, 147.1. HRMS (EI) anal. calcd for C~15~H~14~N~2~O~2~ (M^+^): 254.1055. Found: 254.1056.

General Procedure for the Oxidation of **5**--**7**^[@ref10],[@ref12]^ {#sec4.5}
----------------------------------------------------------------------

To a stirred solution of **5** (0.1 mmol) in acetonitrile/H~2~O (7:3, 2 mL) in ice bath was added dropwise a solution of ceric ammonium nitrate (0.4 mmol) in acetonitrile/H~2~O (9:1, 2 mL). The reaction mixture was stirred for 20 min at room temperature, during which time the color turned brown. The reaction mixture was poured into cold water and then extracted with ethyl acetate (40 mL). Removal of the solvent and recrystallization from dichloromethane and hexane mixture gave **7**.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7a**) {#sec4.5.1}

Brown solid (21 mg, 84%). Mp 216--219 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.11 (s, 2H), 7.34--7.38 (m, 1H), 7.50--7.54 (m, 1H), 7.89--7.92 (m, 2H), 9.08 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 119.5, 120.2, 124.1, 126.6, 128.4, 128.5, 131.4, 132.8, 135.6, 136.4, 142.2, 179.7, 182.8. HRMS (EI) anal. calcd for C~14~H~7~N~3~O~2~ (M^+^): 249.0538. Found: 249.0540.

### 6-Methylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7b**) {#sec4.5.2}

Brown solid (23 mg, 86%). Mp 202--205 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.00 (s, 3H), 6.52 (d, *J* = 8.8 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.79--6.82 (m, 1H), 6.93 (d, *J* = 7.8 Hz, 1H), 7.09--7.12 (m, 1H), 7.86 (dd, *J* = 7.9 Hz and 1.1 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 10.9, 113.4, 118.9, 122.4, 123.1, 123.7, 123.8, 124.2, 128.4, 130.6, 131.8, 140.9, 146.9, 178.9, 179.9. HRMS (EI) anal. calcd for C~15~H~9~N~3~O~2~ (M^+^): 263.0695. Found: 263.0693.

### 6-Phenylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7c**) {#sec4.5.3}

Brown solid (26 mg, 81%). Mp 239--241 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.91 (d, *J* = 10.3 Hz, 1H), 7.00 (d, *J* = 10.3 Hz, 1H), 7.23--7.26 (m, 1H). 7.54--757 (m, 1H), 7.59--7.64 (m, 3H), 7.80 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.54--8.56 (m, 2H), 9.16 (dd, *J* = 8.5, 1.0 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 119.9, 122.2, 123.0, 124.9, 127.7, 127.9, 128.8, 130.6, 132.2, 133.3, 134.3, 138.4, 140.4, 145.1, 149.7, 164.7, 178.8, 180.9. HRMS (EI) anal. calcd for C~20~H~11~N~3~O~2~ (M^+^): 325.0851. Found: 325.0852.

### 6-Benzylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7d**) {#sec4.5.4}

Brown solid (27 mg, 79%). Mp 250--253 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.87 (s, 2H), 6.68 (d, *J* = 10.3 Hz, 1H), 6.73 (d, *J* = 10.3 Hz, 1H), 7.05--7.09 (m, 1H). 7.19--7.22 (m, 1H), 7.26--7.29 (m, 2H), 7.35--7.38 (m, 1H), 7.61--7.64 (m, 3H), 8.73--8.75 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 45.7, 114.8, 116.2, 120.5, 122.2, 125.1, 126.2, 127.9, 128.7, 128.8, 130.2, 134.8, 136.3, 137.9, 148.3, 163.8, 169.7, 178.1, 182.8. HRMS (EI) anal. calcd for C~21~H~13~N~3~O~2~ (M^+^): 339.1008. Found: 339.1009.

### 6-Propylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7e**) {#sec4.5.5}

Brown solid (26 mg, 88%). Mp 232--235 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.96 (t, *J* = 7.4 Hz, 3H), 1.82--1.89 (m, 2H), 2.35--2.39 (2, 2H), 6.53 (d, *J* = 10.4 Hz, 1H), 6.71 (d, *J* = 10.4 Hz, 1H), 6.93--6.96 (m, 1H), 7.19--7.22 (m, 1H), 7.70 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.64 (dd, *J* = 8.4, 0.7 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 12.2, 17.3, 34.8, 119.6, 121.0, 124.4, 125.3, 126.7, 127.1, 128.6, 128.9, 136.7, 147.4, 148.1, 171.2, 179.6, 181.1. HRMS (EI) anal. calcd for C~17~H~13~N~3~O~2~ (M^+^): 291.1008. Found: 291.1006.

### 6-(Pyridin-3-yl)benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7f**) {#sec4.5.6}

Brown solid (26 mg, 80%). Mp 278--280 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.42--6.44 (m, 1H), 6.65 (d, *J* = 10.3 Hz, 1H), 6.83 (d, *J* = 10.3 Hz, 1H), 7.00--7.07 (m, 2H), 7.24--7.28 (m, 2H), 7.29--7.32 (m, 1H), 7.44--7.47 (m, 1H), 7.64--7.66 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 122.1, 124.8, 126.4, 127.3, 127.7, 127.9, 128.2, 129.2, 132.0, 133.1, 133.2, 133.4, 138.1, 142.3, 146.9, 152.5, 178.3, 180.3. HRMS (EI) anal. calcd for C~19~H~10~N~4~O~2~ (M^+^): 326.0804. Found: 326.0802.

### 6-(Thiophen-2-yl)benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7g**) {#sec4.5.7}

Brown solid (26 mg, 77%). Mp 268--269 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.42 (dd, *J* = 7.7, 1.6 Hz, 1H), 6.69 (d, *J* = 10.3 Hz, 1H), 6.78 (d, *J* = 10.3 Hz, 1H), 7.13--7.16 (m, 1H), 7.18--7.22 (m, 1H), 7.44--7.49 (m, 2H), 7.55 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.79--7.81 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 124.3, 126.2, 127.8, 128.8, 129.0, 130.1, 132.1, 133.0, 133.4, 133.8, 135.3, 137.5, 142.0, 146.7, 151.9, 163.3, 177.5, 180.6. HRMS (EI) anal. calcd for C~18~H~9~N~3~O~2~S (M^+^): 331.0415. Found: 331.0416.

### 1,2,3,4-Tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7h**) {#sec4.5.8}

Brown solid (21 mg, 81%). Mp 215--217 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.90--2.00 (m, 4H), 2.90--2.93 (m, 2H), 3.14--3.16 (m, 2H), 6.72 (d, *J* = 10.3 Hz, 1H), 6.83 (d, *J* = 10.3 Hz, 1H), 9.58 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 22.6, 23.6, 24.3, 32.3, 119.0, 120.6, 137.6, 139.5, 144.0, 146.4, 148.5, 150.6, 180.8, 181.3. HRMS (EI) anal. calcd for C~14~H~11~N~3~O~2~ (M^+^): 253.0851. Found: 253.0854.

### 6-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7i**) {#sec4.5.9}

Brown solid (23 mg, 87%). Mp 197--200 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.55 (s, 3H), 1.77--1.92 (m, 4H), 2.90--2.94 (m, 2H), 2.98--3.00 (m, 2H), 6.95 (d, *J* = 10.4 Hz, 1H), 7.01 (d, *J* = 10.4 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.0, 21.2, 21.5, 25.0, 32.7, 123.4, 129.6, 132.5, 136.0, 137.0, 143.6, 148.9, 166.5, 176.0, 181.8. HRMS (EI) anal. calcd for C~15~H~13~N~3~O~2~ (M^+^): 267.1008. Found: 267.1007.

### 6-Phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7j**) {#sec4.5.10}

Brown solid (27 mg, 83%). Mp 233--235 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.77--1.82 (m, 2H), 1.87--1.92 (m, 2H), 2.90--2.94 (m, 2H), 2.98--3.00 (m, 2H), 6.84 (d, *J* = 10.4 Hz, 1H), 6.90 (d, *J* = 10.4 Hz, 1H), 7.31--7.32 (m, 2H), 7.51--7.53 (m, 3H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 20.7, 20.9, 24.7, 32.4, 123.1. 126.3, 128.2, 128.4, 129.8, 132.2, 135.7, 136.7, 139.2, 143.3, 148.6, 166.2, 175.7, 181.5. HRMS (EI) anal. calcd for C~20~H~15~N~3~O~2~ (M^+^): 329.1164. Found: 329.1162.

### 6-Benzyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7k**) {#sec4.5.11}

Brown solid (27 mg, 80%). Mp 219--222 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.90--1.98 (m, 4H), 2.88--2.91 (m, 2H), 3.12--3.14 (m, 2H), 3.92 (s, 2H), 6.81 (d, *J* = 10.4 Hz, 1H), 6.87 (d, *J* = 10.4 Hz, 1H), 7.24--7.27 (m, 1H), 7.31--7.34 (m, 2H), 7.66--7.69 (m, 2H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 22.2, 23.0, 23.7, 31.6, 42.0, 115.2, 118.0, 126.4, 127.6, 128.0, 128.5, 129.4, 134.9, 145.5, 148.6, 150.3, 150.4, 176.9, 179.5. HRMS (EI) anal. calcd for C~21~H~17~N~3~O~2~ (M^+^): 343.1321. Found: 343.1322.

### 6-Propyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7l**) {#sec4.5.12}

Brown solid (24 mg, 80%). Mp 208--210 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.83--0.86 (m, 3H), 1.77--1.82 (m, 2H), 1.87--1.92 (m, 2H), 1.98--2.06 (m, 2H), 2.35--2.38 (m, 2H), 2.90--2.92 (m, 2H), 2.98--3.00 (m, 2H), 6.81 (d, *J* = 10.4 Hz, 1H), 6.87 (d, *J* = 10.4 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.0, 19.1, 21.8, 22.0, 25.7, 33.4, 40.9, 124.2, 125.7, 133.3, 136.8, 137.8, 144.4, 149.7, 167.3, 176.8, 182.6. HRMS (EI) anal. calcd for C~17~H~17~N~3~O~2~ (M^+^): 295.1321. Found: 295.1322.

### 2-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazoline-8,11-dione (**7m**) {#sec4.5.13}

Brown solid (20 mg, 76%). Mp 207--209 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.12 (d, *J* = 6.6 Hz, 3H), 1.53--161 (m, 1H), 1.92--2.06 (m, 2H), 2.43--2.49 (m, 1H), 2.90--2.95 (m, 1H), 2.98--3.05 (m, 1H), 3.15--3.19 (m, 1H), 6.71 (d, *J* = 10.4 Hz, 1H), 6.77 (d, *J* = 10.4 Hz, 1H), 9.03 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.1, 28.6, 30.3, 32.9, 34.3, 116.1, 117.1, 133.2, 136.5, 143.1, 145.3, 149.2, 165.3, 177.2, 180.7. HRMS (EI) anal. calcd for C~15~H~13~N~3~O~2~ (M^+^): 267.1008. Found: 267.1009.

### 2,3,4,5-Tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*c*\]cyclohepta\[*e*\]pyrimidine-9,12-dione (**7n**) {#sec4.5.14}

Brown solid (24 mg, 89%). Mp 216--218 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.80--1.84 (m, 2H), 1.97--2.02 (m, 4H), 2.92--2.95 (m, 2H), 3.62--3.64 (m, 2H), 6.88 (d, *J* = 10.4 Hz, 1H), 6.94 (d, *J* = 10.4 Hz, 1H), 9.06 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.1, 26.4, 29.7, 31.0, 33.0, 120.2, 123.2, 132.3, 135.8, 143.4, 148.7, 166.3, 175.8, 181.6. HRMS (EI) anal. calcd for C~15~H~13~N~3~O~2~ (M^+^): 267.1008. Found: 267.1009.

### 1,2,3,4,5,6-Hexahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cycloocta\[*e*\]pyrimidine-10,13-dione (**7o**) {#sec4.5.15}

Brown solid (21 mg, 73%). Mp 229--231 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.27--1.32 (m, 2H), 1.38--1.42 (m, 2H), 1.66--1.71 (m, 2H), 1.82--1.87 (m, 2H), 2.73--2.76 (m, 2H), 3.59--3.61 (m, 2H), 6.85 (d, *J* = 10.3 Hz, 1H), 6.89 (d, *J* = 10.3 Hz, 1H), 9.10 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.7, 25.3, 27.7, 28.3, 28.9, 31.1, 122.9, 125.8, 133.6, 140.1, 146.3, 151.0, 151.6, 157.1, 174.0, 181.9. HRMS (EI) anal. calcd for C~16~H~15~N~3~O~2~ (M^+^): 281.1164. Found: 281.1162.

### 1,2,3,4,5,6,7,8,9,10-Decahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cyclododeca\[*e*\]pyrimidine-14,17-dione (**7p**) {#sec4.5.16}

Brown solid (24 mg, 70%). Mp 245--247 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.29--1.39 (m, 8H), 1.43--1.53 (m, 4H), 1.56--1.61 (m, 2H), 1.70--1.76 (m, 2H), 2.82--2.85 (m, 2H), 3.57--3.60 (m, 2H), 6.85 (d, *J* = 10.3 Hz, 1H), 6.91 (d, *J* = 10.3 Hz, 1H), 9.30 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 20.9, 21.2, 24.1, 24.4, 24.7, 25.0, 25.1, 25.3, 26.5, 28.1, 123.0, 124.9, 133.3, 139.7, 146.0, 150.4, 151.0, 157.8, 173.9, 181.5. HRMS (EI) anal. calcd for C~20~H~23~N~3~O~2~ (M^+^): 337.1790. Found: 337.1792.

### 4-Methyl-3-phenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine-6,9-dione (**7q**) {#sec4.5.17}

Brown solid (21 mg, 73%). Mp 228--230 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.17 (s, 3H), 6.56 (d, *J* = 10.4 Hz, 1H), 6.75 (d, *J* = 10.4 Hz, 1H), 7.47--7.50 (m, 3H), 7.51--7.54 (m, 2H), 9.42 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.6, 120.6, 122.1, 127.4, 127.5, 129.0, 131.9, 133.4, 138.3, 144.8, 145.9, 150.4, 157.5, 172.4, 181,4. HRMS (EI) anal. calcd for C~17~H~11~N~3~O~2~ (M^+^): 289.0851. Found: 289.0849.

### 3,4-Diphenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine-6,9-dione (**7r**) {#sec4.5.18}

Brown solid (25 mg, 71%). Mp 249--252 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.74 (d, *J* = 10.2 Hz, 1H), 6.89 (d, *J* = 10.2 Hz, 1H), 7.24--7.27 (m, 2H), 7.29--7.31 (m, 2H), 7.33--7.36 (m, 6H), 9.11 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 120.7, 125.8, 127.5, 127.8, 128.1, 128.9, 129.0, 129.3, 134.2, 134.3, 136.1, 136.5, 136.7, 144.1, 148.5, 162.2, 176.0, 181.3. HRMS (EI) anal. calcd for C~22~H~13~N~3~O~2~ (M^+^): 351.1008. Found: 351.1005.

Experimental Procedure for Mechanism Study {#sec4.6}
------------------------------------------

A 5 mL microwave reaction tube was charged with **8** (0.086 g, 0.3 mmol) and **2** (0.073 g, 0.6 mmol), together with CuI (0.006 g, 0.03 mmol), [l]{.smallcaps}-proline (0.010 g, 0.09 mmol), Cs~2~CO~3~ (0.293 g, 0.9 mmol), and DMF (3 mL). The reaction mixture was heated to 130 °C for 1 h by microwave irradiation at 100 W initial power. The mixture was then cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to remove inorganic components. Removal of the solvent left a crude mixture, which was separated by TLC (dichloromethane/MeOH = 97:3) to give **9**.

### *N*-(2-(1-Methyl-1*H*-benzo\[*d*\]imidazol-2-yl)phenyl)benzamide (**9**) {#sec4.6.1}

Pale yellow solid (69 mg, 70%). Mp 267--269 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.87 (s, 3H), 7.30--7.38 (m, 3H), 7.39--7.43 (m, 2H), 7.46--7.59 (m, 5H), 7.76--7.78 (m, 2H), 7.82--7.84 (m, 1H), 12.18 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 31.7, 109.6, 119.9, 122.5, 122.8, 123.0, 127.0, 127.5, 128.6, 128.7, 129.5, 129.7, 130.3, 131.3, 132.5, 136.6, 143.0, 153.8, 165.4. HRMS (EI) calcd for C~21~H~17~N~3~O (M^+^): 327.1372. Found: 327.1372.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00805](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00805).Copies of ^1^H and ^13^C NMR spectra ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00805/suppl_file/ao8b00805_si_001.pdf))
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